SOLUMAG OS 20FL 1.5G 10ML

SOLUMAG 1.5 G ORAL FUTURE

active ingredients

A 10 ml bottle contains: active ingredient: magnesium pidolatrous g 1.5 For the full list of excipients, see paragraph 6.1.

Excellent

For each bottle: sucrose; orange juice; mandarin aroma; sodium saccharin; methyl p–hydroxybenzoate sodium; propyl p–hydroxybenzoate sodium; purified water.

Therapeutic indications

In neurology and pediatrics: clinical paintings expressing a state of hypereccitability of the central and peripheral nervous system, supported by a deficiency of magnesium. In obstetrics: vomiting, insomnia, irritability, muscle cramps, painful contractions of the uterus, eclampsia.

Contraindications

Severe kidney failure. Hypersensitivity to the active ingredient or any of the excipients. Not to be administered in subjects in digital therapy.

Population

Posology will be determined by the attending physician. The following is indicative: In adult: 2 – 3 bottles for oral use per day. In the child: 2 bottles for oral use per day. Early childhood: 1⁄2 – 1 bottle for oral use per day. Due to the high content of orange juice, it is good to shake the bottle before use.

Conservation

This medicine does not require any special condition of conservation

Warnings

If symptoms persist or aggravate them, please contact your doctor. In patients with kidney failure it is necessary to reduce posology and monitor kidney function and magnesiemia. It is appropriate to consider the possibility that occurs, during treatment, depression of cardiovascular activity and respiratory activity. SOLUMAG contains sucrose: patients suffering from rare hereditary problems of fructose intolerance, glucosegalactose mal absorption, or isomaltase sucrasis failure, should not take this medicine. SOLUMAG it also contains parahydroxybenzoates, which can cause allergic reactions (also delayed).

Interactions

The administration of magnesium can lead to a reduced absorption of tetracyclines and therefore it is recommended not to administer SOLUMAG at the same time to medicines based on tetracyclines, but at 3 – 4 hours distance between administrations. Chinolones should be administered at least 2 hours before or 6 hours after the administration of Magnesium-based products to avoid interference with their absorption. In the case of concomitant administration of magnesium and cholecalciferol it is also recommended to control the calcemy, in order to avoid the possibility of hypercalcemic episodes. We do not recommend the concomitant use of preparations containing calcium salts or phosphate since such products prevent the absorption of magnesium. The simultaneous intake of magnesium-based products with depressing drugs the Central Nevous System can enhance the effects on the magnesium SNC and must be carefully evaluated.

Effects

Rare digestive disorders; diarrhea; abdominal pain. Exceptional cases of individual intolerance to ion have been reported, which can be treated with oral or parental antihistamines.

Overdosing

Cases of hypermagnesia have been reported as a result of mass administration of magnesium or during the treatment of patients with severe kidney failure. The symptoms observed were: heart rhythm disorders, respiratory depression and neuromuscular transmission disorders. The treatment uses rehydration with restoration of a plentiful diuresis or forced diuresis. In case of kidney failure, dialysis treatment is recommended.

It is recommended that in pregnancy and breastfeeding the drug take place under medical control and in cases of actual need.

Source: Farmadati